Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2021 Financial Results on March 4, 2022
Rapid Micro Biosystems (Nasdaq: RPID) will announce its fourth quarter and full year 2021 financial results on March 4, 2022, before the market opens. The management team will host a webcast conference call at 8:30 a.m. EST on the same day, accessible via their website. Rapid Micro specializes in automated solutions for microbial quality control in pharmaceutical manufacturing, ensuring faster and safer healthcare product releases. Their flagship product, the Growth Direct System, modernizes traditional testing methods, enhancing efficiency and regulatory compliance.
- Scheduled release of Q4 and full year 2021 financial results, indicating transparency.
- Innovative Growth Direct System improves operational efficiency and compliance.
- None.
LOWELL, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2021 financial results on Friday, March 4, 2022, prior to the market open.
In conjunction with the release, Rapid Micro’s management team will host a webcast conference call at 8:30 a.m. EST on Friday, March 4, 2022. The live call will be accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
FAQ
When will Rapid Micro Biosystems release its Q4 2021 financial results?
What is the significance of the Growth Direct System for Rapid Micro Biosystems?
How can I access the financial results conference call for Rapid Micro Biosystems?
